HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy
Loading...
Date
2020
Journal Title
Journal ISSN
Volume Title
Publisher
SAMA
Abstract
: The integrase (IN) strand-transfer inhibitor (InSTI)
dolutegravir (DTG) is now recommended by the World Health
Organization as part of salvage and/or first-line combination
antiretroviral therapy (cART).[1] DTG has a high genetic barrier
against developing resistance and is effective against all strains
that previously exhibited resistance-associated mutations (RAMs)
against other cART regimens.[2] Recommendations to use DTG were
delayed owing to preliminary findings from Botswana that indicated
potential safety concerns in pregnancy, with a small increased risk of
neural tube defects.[3] Studies that investigated the safety and efficacy
of DTG now support its use in all populations, including pregnant
women and those of childbearing potential
Description
Keywords
HIV-1, Africa, Antiretroviral therapy, Drug safety, Pregnant women
Citation
Cloete, R. et al. (2020). HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy. South African Medical Journal, 110(9), 827